Neoadjuvant treatment of breast cancer

Annals of Oncology

Volumn 23, Issue SUPPL. 10, 2012, Pages

  Thompson, A M ^a   Moulder Thompson, S L ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biomarker; HER2; Neoadjuvant; Preoperative; Response; Targeted therapy

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EVEROLIMUS; EXEMESTANE; FLOXURIDINE; FULVESTRANT; LAPATINIB; LETROZOLE; METFORMIN; PACLITAXEL; PERTUZUMAB; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INTERMETHOD COMPARISON; MONOTHERAPY; OUTCOME ASSESSMENT; PARTIAL MASTECTOMY; PATIENT ASSESSMENT; PREOPERATIVE EVALUATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; THROMBOEMBOLISM; TREATMENT RESPONSE; VAGINA DISCHARGE;

EID: 84866774263     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds324     Document Type: Article

References (33)

1. Kuerer HM, Newman LA, Smith TL et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-469.
2. Guarneri V, Broglio K, Kau SW et al. Prognostic value of pathological complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006; 24: 1037-1044.
3. Deo SV, Bhutani M, Shukla NK et al. Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0). J Surg Oncol 2003; 84(4): 192-197.
4. Mieog JSD, van der Hage JA, van de Velde CJH. Neoadjuvant chemotherapy for opérable breast cancer. Br J Surg 2007; 94: 1198-1200.
5. Shet T, Agrawal A, Chinoy R et al. Changes in the tumor grade and biological markers in locally advanced breast cancer after chemotherapy-implications for a pathologist. Breast J 2007; 13(5): 457-464.
6. Mann GB, Fahey VD, Feleppa F et al. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol 2005; 23: 5148-5154.
7. Escobare PF, Patrick RJ, Rybicki LA et al. Prognostic significance of residual breast disease and axillary node involvement for patients who had primary induction chemotherapy for advanced breast cancer. Ann Surg Oncol 2006; 13 (6): 783-787.
8. Pierga JY, Mouret E, Diéras V et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer 2000; 83: 1480-1487.
9. Cody HS. 3rd Sentinel lymph node biopsy for breast cancer: indications, contraindications and new directions. J Surg Oncol 2007; 95: 440-442.
10. Tan VKM, Goh BKP, Fook-Chong S et al. The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer-a systematic review and meta-analysis. J Surg Oncol 2011; 104: 97-103.
11. Manton DJ, Chaturverdi A, Hubbard A et al. Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer 2006; 94: 427-435.
12. Symmans WF, Peintinger F, Hatzis C et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007; 25: 4414-4422.
13. Symmans WF, Hatzis C, Sotiriou C et al. Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol 2010; 28: 4111-4119.
14. Hatzis C, Pusztai L, Valero V et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. J Am Med Assoc 2011; 305: 1873-1881.
15. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3808-3816.
16. Seo JH, Kim YH, Kim JS. Meta analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal women with hormone receptor positive breast cancer. Cancer Chemother Pharmacol 2009; 63: 261-266.
17. Llonbart-Cussac A, Guerrero A, Galan A et al. Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer. Clin Transl Oncol 2012; 14: 125-131.
18. Ellis MJ, Suman VJ, Hoog J et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol 2011; 29: 2342-2349.
19. Semiglazov VF, Semiglazov VV, Dashyan GA et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with oestrogen receptor-positive breast cancer. Cancer 2007; 110(2): 244-254.
20. Huober J, von Minckwitz G, Denkert C et al. Effect of neoadjuvant anthracyclinetaxane-based chemotherapy in different biological breast cancer phénotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 2010; 124: 133-140.
21. Von Minckwitz G, Loibl S, Untch M. What is the current standard of care for anti-HER2 neoadjuvant therapy in breast cancer? Oncology (Williston Park) 2012; 26: 20-26.
22. Zambetti M, Mansutti M, Gomez P et al. Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II). Breast Cancer Res Treat 2012: 132; 843-851.
23. Arun BK, Dhinghra K, Valero V et al. Phase III ranodmized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist 2011; 16: 1527-1534.
24. Gianni L, Eiermann W, Semiglazov V et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010; 375: 377-384.
25. Baselga J, Bradbury I, Eidtmann H et al. Lapatanib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379: 633-640.
26. Gianni L, Pienkowski T, Im Y-H et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, openlabel, phase 2 trial. Lancet 2012; 13: 25-32.
27. Hadad S, Iwamoto T, Jordan L et al. Evidence for biological effect of metformin in operable breast cancer: a pre-operative, window of opportunity, randomized trial. Breast Cancer Res Treat 2011; 128: 783-794.
28. Macaskill EJ, Bartlett JMS, Sabine VS et al. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study. Breast Cancer Res Treat 2011; 128: 725-734.
29. Earl HM, Vallier A, Hiller L et al. NeotAnGo: a neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel +/- gemcitabine in the treatment of women with high-risk early breast cancer (EBC): first report of the primary endpoint, pathological complete response (pCR). J Clin Oncol 2009; 27: 15s (Suppl; abstr 522).
30. Poole CJ, Hiller L, Howard HC et al. tAnGo: A randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early-stage breast cancer (EBC). J Clin Oncol 2008; 26(15S): 506.
31. Smith IE, Dowsett M, Ebbs SR et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen or both in combination: the immediate peroperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicentre double-blind randomized trial. J Clin Oncol 2005; 23: 5108-5116.
32. ATAC Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer first results of the ATAC randomised trial. Lancet 2012; 359: 2131-2139.
33. Kong X, Moran MS, Zhang N et al. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer 2011; 47: 2084-2090